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September 2018 recovery after stroke, 13, [15] [16] [17] providing important insights on poststroke recovery mechanisms. In the recent years, there has been increased focus on changes beyond the peri-infarct regions, as stroke causes network-wide changes in the brain. [18] [19] [20] Human and animal studies have reported functional and structural changes in the contralesional cortex, suggesting that stroke-connected brain regions such as contralesional cortex may be involved in brain repair and recovery after stroke.
In this study, our goal is to elucidate the intrinsic mechanisms of spontaneous recovery after stroke without any external intervention. To achieve this, we directly investigated the molecular signature of mice that naturally recovered after stroke. By directly comparing the molecular responses between naturally recovered and nonrecovered stroke mice, this unperturbed approach may reveal novel mechanisms that have been masked by studies using external restorative therapies. Our study is designed to (1) observe a natural, spontaneous recovery of function in mice after stroke; (2) use unbiased cluster analysis to determine the presence of distinct recovery groups; (3) conduct a novel in-depth lesion analysis to determine if the differential recovery outcome was related to lesion size/locations; (4) use next-generation RNAsequencing (RNA-seq) technology to investigate the transcriptome of both ipsilesional primary motor cortex (iM1) and contralesional primary motor cortex (cM1) in recovered and nonrecovered stroke mice. Understanding the intrinsic mechanisms driving spontaneous recovery will be invaluable for the development of drugs targeting these mechanisms to promote recovery after stroke.
Methods
Below are the main methods necessary to comprehend the results (details in the online-only Data Supplement). Data supporting the findings of this study are available from the corresponding author on reasonable request.
Animals
All animals used in this study were C57BL/6J wild-type male mice (11-13 weeks of age). To keep the consistency of same gender, female mice were not used in this discovery study. A total of 75 mice were used in this study, of which 33 stroke mice and 7 nonstroke sham mice were included for analysis ( Figure I in the online-only Data Supplement for inclusion/exclusion criteria). All experiments were conducted in compliance with animal care laws and institutional guidelines and approved by the Stanford Institutional Animal Care and Use Committee. Mice were randomized and subjected to transient middle cerebral artery occlusion for 30 minutes. All behavior tests were performed by blinded observers on the day before stroke surgery and on poststroke day (PD) 4, 8, and 14.
Semiautomated Lesion Analysis (Magnetic Resonance Imaging, Histology)
A subset of stroke mice was scanned at PD2 using 7-Tesla magnetic resonance imaging (MRI) system. T2-weighted images (T2WI) were acquired and used to quantify the individual infarct volume. For histology, stroke mice were euthanized at PD15 and processed for immunostaining to visualize infarct. Using our pipeline, MRI-based and immunostaining-based images were registered with the Allen brain reference mouse atlas (ARA), and lesion masks were overlaid with the corresponding ARA labels for quantification of infarct volume (MRI) or size (immunostaining).
RNA-Seq Analysis
A subset of stroke mice was selected and their primary motor cortices (ipsilesional and contralesional) were processed for RNAseq transcriptome analysis using Hiseq 4000 (Illumina, Hayward, CA). Raw sequences were processed for quality control, trimming (Trimmomatic version 0.36), and alignment (STAR/2.5.1b). Downstream analyses were performed using R (version 3.1.1), with edgeR and limma package with voom method. Differentially expressed genes (DEGs) were further analyzed by Ingenuity Pathway Analysis (IPA) software (QIAGEN) to provide the significant canonical pathway, diseases, and functions. Quantitative realtime PCR (qPCR) was used to validate the expression of candidate genes relative to sham group.
Statistical Analysis
For the horizontal rotating beam data (distance and speed data), we performed unsupervised hierarchical clustering analysis (H-clustering) to determine presence of distinct clusters. In addition, gap statistics (clusGap function in R) was used to estimate the number of clusters in all 33 stroke mice included for the analysis. Gap statistics have been previously demonstrated to outperform other methods in estimating the number of clusters in a given data set. 21 For pathway analysis, statistical tests were performed by the Ingenuity Pathway Analysis software using Fisher exact test. Prism 7.03 (GraphPad Software, Inc, La Jolla, CA) was used to perform statistics for the following results. For the quantification of infarct size (% infarct-volume by T2WI or -area by histology) or infarct location (% infarct-volume or -area per region) data, we performed either 2-tailed unpaired Student t test or 2-way ANOVA followed by Bonferroni post hoc test. Spearman correlation analysis was used for (1) thalamic lesion and recovery; (2) RNA-seq-based gene expression and recovery; and (3) infarct size and recovery. For qPCR studies, 1-way ANOVA followed by Bonferroni test was used to analyze relative gene expression level to nonstroke sham mice. Significance level was set at P<0.05.
Results

Cluster Analysis of the Horizontal Rotating Beam Test Revealed 2 Distinct Recovery Groups
After stroke, we observed the sensory-motor recovery using established behavior tests (see experimental timeline and design in Figure 1A ). We chose the horizontal rotating beam test as the primary test because it has been previously demonstrated as a reliable and sensitive test for detecting long-term deficit after stroke. 22, 23 Distance data were used for cluster analysis, as it is the most fundamental and unbiased measure of the rotating beam test. We performed unsupervised hierarchical clustering analysis using the distance data from the horizontal beam test. Cluster analysis indicated the emergence of 2 distinct recovery groups at PD14 ( Figure 1B ): a spontaneously recovered group (n=9) and a nonrecovered group (n=24; Figure 1C and 1D). Nonstroke sham behavior data were included as a comparison. All subsequent analyses were performed based on this group separation, including body weight, vertical stationary beam test, and mNS data ( Figure II in the online-only Data Supplement).
Infarct Size and Location Did Not Differ Between Recovery and Nonrecovery Groups
Next, we examined whether the differential recovery outcome between recovered and nonrecovered groups was because of variations in the infarct size and location. Using a semiautomated in-depth lesion mapping analysis, we performed a comprehensive evaluation on the infarct size and location of the 2 recovery groups. Cerebral infarcts were visualized either by T2WI at PD2 (Figure 2 ) in 22 mice or by histology at PD15 by CD68 and MAP2 (microtubule associated protein 2) immunostaining ( Figure 3 ) in the remaining 11 mice. T2WI sequence parameters were listed in Table I in the online-only Data Supplement, and the coregistrations for MRI/histology to ARA were shown in Figure III in the onlineonly Data Supplement. Our analysis indicated that there was no significant difference in % infarct volume (measured by T2WI on PD2; Figure 2B ; P=0.533) or % infarct area (measured by histology at PD15 at the striatal [Str] and thalamohippocampal [Hpx] levels between the groups; Figure 3B ; P=0.794 Stx level, P=0.356 Hpx level), although the variation in sample size between the groups could mask any significance in the infarct volume. Overall the incidence of brain regions affected by stroke was similar between recovered and nonrecovered, with a trend toward involvement of a larger portion of the medial thalamus in nonrecovered ( Figures 2C  and 3C ). However, in the voxel-wise analysis, there was no significant difference in lesion location quantified by MRI or histology ( Figures 2D and 3D ). Nevertheless, we examined whether thalamic lesions can affect behavior outcome. Correlation analysis of thalamic lesions and behavior outcome showed that there was no significant correlation ( Figure 
RNA-Seq Transcriptome Analysis in Recovered and Nonrecovered Stroke Mice
We analyzed the transcriptome of iM1 and cM1 in recovered and nonrecovered stroke mice using RNA-seq. The rotating beam behavior results for the 8 stroke mice analyzed with RNA-seq were shown in Figure 4A (recovered, n=3; nonrecovered, n=5). T2WI at PD2 indicated that both groups exhibited comparable cerebral infarcts ( Figure 4B, left) . For the 
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RNA-seq study, mice were euthanized at PD15, and the iM1 and cM1 were dissected ( Figure 4B , right) and processed for RNA-seq. Unsupervised cluster analysis by multidimensional scaling plots of the transcriptome profile showed distinct cluster between iM1 and cM1 samples regardless of recovery outcome ( Figure 4C , left). Despite the lack of primary ischemic injury in iM1, the unsupervised transcriptome profiling indicated that the transcriptome profile of the primary motor cortex was predominantly affected by stroke. Supervised hierarchical clustering analysis of the iM1 and cM1 samples (imposed minimum threshold: P<0.05) showed distinct cluster separation in cM1 that corresponded to recovered and nonrecovered group (Figure 4C, right) . However, cluster analysis of iM1 samples showed 3 groups ( Figure 4C , middle), despite similar cerebral infarct. Heat maps and the top upregulated and downregulated genes in iM1 and cM1 were shown in Figure 4D , respectively. Differential transcriptome analysis revealed 263 DEGs in the iM1 (131 upregulated and 132 downregulated; Figure 4D , left) and 417 DEGs in the cM1 (147 upregulated and 270 downregulated; Figure 4D , right) in the recovered group. Top significant upregulated or downregulated genes in the iM1 or cM1 of the recovered group were highlighted in Figure 4D ( Table II in 
RNA-Seq Transcriptome Analysis Highlights Distinct Pathways in the Contralesional Motor Cortex of Recovered Stroke Mice
To further investigate the molecular mechanisms driving spontaneous recovery, we used Ingenuity Pathway Analysis to analyze the DEGs in both iM1 and cM1 (imposed minimum threshold: P<0.05, absolute expression log fold change >0.26) and reported relevant canonical pathways, major diseases, molecular and cellular functions ( Figure 5 ). Canonical pathways in the iM1 include the planar cell polarity pathway, axonal guidance signaling, and BMP (bone morphogenetic protein) signaling. Major diseases, molecular and cellular functions in the iM1 include organismal injuries and abnormalities, cell death and survival, cellular growth and proliferation, cell development, cell signaling, and behavior. Other significant canonical pathways in the iM1 include the adipogenesis pathway, TGF-β (transforming growth factor-β) signaling, complement system, p38 MAPK (mitogen-activated protein kinase) signaling, leukocyte extravasation signaling, cAMP-mediated signaling and Wnt/Calcium (Ca+) signaling ( Figure 5A ).
Canonical pathways in the cM1 included axonal guidance signaling, Wnt/Ca+ pathway and cAMP-mediated signaling ( Figure 5B ). Major diseases and molecular and cellular functions in the cM1 include organismal injuries and abnormalities, cardiovascular disease, neurological disease, cellular movement, cellular growth and proliferation, and immune cell trafficking. Other significant canonical pathways in the cM1 included prostanoid biosynthesis, eicosanoid signaling, agranulocyte adhesion and diapedesis, ILK (integrin-linked kinase) signaling, GPCR (G protein-coupled receptor) signaling, leukocyte extravasation signaling, and epithelial adherens junction signaling ( Figure 5B) .
Genes in the cAMP-Mediated Signaling Pathway Are Significantly Correlated With Recovery
To identify genes that may underlie spontaneous recovery, we examined which DEGs were correlated with recovery by performing correlation analysis between gene expression level (counts per million reported from RNA-seq analysis) of each DEG and behavior recovery outcome (distance data at PD14 from the rotating beam test). Correlation analysis indicated that there were 38 DEGs in the iM1 and 74 DEGs in the cM1 correlated with recovery (Tables III and IV in the online-only Data Supplement). We focused our subsequent analysis in the cM1 because (1) more DEGs in cM1 were correlated with recovery and (2) more distinct separation was found in the supervised hierarchical clustering analysis of the cM1 samples instead of the iM1 samples. Ingenuity Pathway Analysis of the 74 DEGs in cM1 revealed cAMPmediated signaling as the first top significant canonical pathway ( Figure 5C (Table IV in the online-only Data Supplement). These 4 DEGs were all significantly and negatively correlated with functional recovery ( Figure 5D ). Interestingly, cAMP-mediated signaling was also included in the top 10 relevant canonical pathways in the iM1 ( Figure 5A ). In iM1, there was no difference in Adora2a and Drd2 between recovered and nonrecovered mice (P>0.10), whereas Pde10a expression was significantly decreased (log FC=−0.217, P=0.015) and Ptger4 was significantly increased (log FC=0.628, P=0.033) in the recovered mice. Most of these 4 genes (except for Pde10a) in the iM1 were not significantly correlated with functional recovery.
qPCR Verification of Candidate Genes in the cAMP Signaling Pathway
Next, we used qPCR to validate the 4 DEGs in the cAMP pathway in cM1. qPCR successfully validated 3 out of 4 genes in this pathway, namely Adora2a, Drd2, and Pde10a ( Figure 6 ). Both Adora2a and Drd2 were significantly upregulated in nonrecovered stroke mice when compared with nonstroke sham mice. Interestingly, Adora2a, Drd2, and Pde10a were significantly reduced in recovered mice, to a level similar to sham. As Adora2a, Drd2, and Pde10a are known to be highly expressed in the striatum, [24] [25] [26] we also examined their expression in the contralesional somatosensory cortex and striatum. Interestingly, all 3 genes were selectively decreased in the cM1 of recovered mice, but not in contralesional somatosensory cortex nor contralesional somatosensory striatum ( Figure 6 ).
Discussion
To our knowledge, this is the first study to investigate the molecular signature in the motor cortex of stroke mice that 15 . A, Representative coronal brain images of MAP2 (microtubule associated protein 2; green) and CD68 (red) immunostaining at the striatal (Str) and thalamo-hippocampal (Hpx) levels from recovered and nonrecovered mice at PD15. Note that the CD68-positive area was predominantly overlaid on the MAP2-negative neuronal loss area in the merged images. Scale bar=1 mm. B, Bar graph demonstrated the average % infarct area over the whole brain section area (mean±SEM; n=5 recovered, n=6 nonrecovered). C, Incidence maps at the striatal and hippocampal levels were shown. Stroke lesion was expressed as color map (% of mice with stroke lesion) overlaid to the Allen brain reference mouse atlas (ARA). D, Semiautomated quantification of % infarct area per selected region at Str (upper) and Hpx (lower) level, respectively. Data were expressed as mean±SEM (n=5 recovered, n=6 nonrecovered).
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naturally recovered without external intervention. By directly comparing the molecular responses between naturally recovered and nonrecovered stroke mice, our approach may reveal novel molecular signature that have been masked by studies using external restorative treatments. Our data showed that stroke mice with comparable infarcts can exhibit differential functional recovery outcomes. RNA-seq transcriptome analysis revealed distinct biological pathways in both the iM1 and cM1 of recovered stroke mice. Our RNA-seq analysis showed that multiple pathways in the iM1 and cM1 are likely to be involved in mediating spontaneous recovery after stroke. Canonical pathways in the iM1 include the axonal guidance signaling, BMP signaling, TGF-β signaling, complement system, MAPK signaling, leukocyte extravasation signaling, cAMP-mediated signaling, and Wnt/Calcium signaling ( Figure 5 ). Most of these pathways in the iM1 are consistent with our knowledge of brain repair pathways after stroke and have been shown to have neuroprotective and neurodegenerative roles. 27 Importantly, our RNA-seq data revealed a panel of spontaneous recovery-related genes (Figures 4 and 5) and reported the involvement of novel biological pathways in cM1. In particular, the cAMP-mediated signaling pathway in the cM1 was highlighted ( Figure 5C , right), with the recovered stroke mice exhibiting a significantly lower expression of 2 GPCRs (Adora2a and Drd2) and Pde10a, to a level similar to sham. Interestingly, the expression of these genes in the cM1 is negatively correlated with behavioral recovery. Our study suggests that Adora2a, Drd2, and Pde10a-mediated signaling may be important for spontaneous recovery after stroke.
To further hone in on the key molecules that mediate spontaneous recovery, we focused on DEGs that were significantly correlated with behavior performance. We have identified a panel of recovery-related genes in both iM1 and cM1 (Tables III and IV in the online-only Data Supplement) . Notably, the cAMP-mediated pathway was the first top pathway highlighted in the cM1, with 4 DEGs (Adora2a, Drd2, Pde10a, and Ptger4) significantly downregulated in the recovered mice, and their expressions were negatively correlated with recovery ( Figure 5C , right; Figure 5D ). Of these 4 genes, we have successfully validated Adora2a, Drd2, Pde10a using qPCR ( Figure 6 ). Interestingly, these genes were selectively decreased in the cM1 of recovered stroke mice, but not in contralesional somatosensory cortex nor contralesional somatosensory striatum. The functions of these genes are briefly discussed below.
Both Adora2a and Drd2 have been studied in acute stroke, [28] [29] [30] [31] however, their role in the brain repair and recovery is unclear, because there are no reports of its role in chronic stage of stroke. Adora2a is a Gs-protein coupled that activates the cAMP-mediated signaling pathway. 32 It has been shown that blocking Adora2a signaling can protect against acute 
September 2018 ischemic excitotoxicity, whereas activating Adora2a signaling within a few hours poststroke can reduce inflammatory cell infiltration after stroke. 28 However, Drd2 is a Gi proteincoupled receptor that inhibits cAMP-mediated signaling. 33 The dopamine system plays a key role in motor learning and neuroplasticity. 34, 35 A recent study showed that activation of Drd2 on astrocytes in acute stroke can reduce neuroinflammation. 31 However, the role of Drd2 in brain repair is also unclear. On the other hand, the role of Pde10a in stroke has not been reported. Recent studies showed that inhibition of Pde10a may be a promising therapeutic strategy for psychiatric and neurodegenerative diseases. 36 Our RNA-seq analysis highlights these genes as potential targets for enhancing stroke recovery; however, the functional consequences of these genes will depend on which cell type showed reduction of these genes in recovered stroke mice, as well as the effects of selective modulations of their signaling in cM1 on recovery outcome. Future studies are required to elucidate the role of these genes in spontaneous recovery and to address whether they act through neuroinflammatory and neuroplasticity mechanisms.
In conclusion, we reported the first RNA-seq transcriptome in the motor cortex of stroke mice that naturally recovered and unraveled the intrinsic molecular signature of spontaneous recovery after stroke in mice. We revealed a panel of recovery-related genes and highlighted canonical pathways in the cM1 of recovered stroke mice, specifically the cAMP-mediated signaling pathway involving Adora2a, Drd2, and Pde10a. Our data indicate that Adora2a, Drd2, and Pde10a signaling in the cM1 may play important roles in stroke recovery. Developing drugs that target these candidates during different phases of recovery may provide beneficial recovery outcome in stroke patients. 
